Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-10-02

Clinical Trial Update: ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of ME-344 combined with Hycamtin (topotecan) in solid tumors was terminated; results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Hycamtin (Topotecan)
  • ME-344

Snippet

Sponsor: MEI Pharma, Inc. | Conditions: Solid Tumors | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2017-10-02